Cryptocurrencies
Agenus stock doubles as biotech narrows Phase 3 bet
Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of Read more…